Psoriatic arthropathy

5 trials 3 recruiting MedDRA PT
5 Registered trials
3 Recruiting
3 Unique sponsors
13 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
JAK inhibitor 3 substances
Monoclonal antibody (human) 3 substances
Unknown / small molecule 2 substances
Monoclonal antibody (humanized) 2 substances
Receptor fusion protein 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Monoclonal antibody 1 substance
Phase III: 4 Other: 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

4 trials
  • Takeda Development Center Americas Inc. Commercial
    APREMILAST, APREMILAST; ZASOCITINIB
    2024-513111-27-00 12 countries 2025 n=708
    Recruiting
  • Takeda Development Center Americas Inc. Commercial
    ZASOCITINIB
    2024-513112-99-00 4 countries 2025 n=194
    Recruiting
  • Takeda Development Center Americas Inc. Commercial
    ZASOCITINIB
    2025-522586-30-00 13 countries n=638
    Pending
  • Universitaetsklinikum Heidelberg AöR Academic
    ABATACEPT; APREMILAST; CERTOLIZUMAB PEGOL; GOLIMUMAB; GUSELKUMAB; IXEKIZUMAB; RISANKIZUMAB; SECUKINUMAB; TOFACITINIB; UPADACITINIB; USTEKINUMAB
    2023-508251-39-00 2 countries 2020 n=370
    Recruiting

Other

1 trial
  • Fresenius Kabi SwissBioSim GmbH Commercial
    IMP not specified
    2025-522422-13-00 1 country 2025 n=160
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Takeda Development Center Americas Inc. Commercial 3 Phase III 2
Fresenius Kabi SwissBioSim GmbH Commercial 1 Other 0
Universitaetsklinikum Heidelberg AöR Academic 1 Phase III 1
New trials by year
2020
1
2025
3
← All indication landscapes